Abstract
The recombinant human IgG1 monoclonal antibody specific for human TNF-a adalimumab (Humira) has been recently introduced for the treatment of moderate/severe psoriasis. Neurological diseases have been rarely described as adverse events of anti-TNF agents. A case of acute respiratory failure due to diaphragmatic weakness following adalimumab therapy for psoriasis is described. A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of adalimumab. Isoniazid and vitamin B6 were co-administered with adalimumab. A symmetric elevation of diaphragms was shown on radiography and fluoroscopy. A pulmonary restrictive defect with a prominent decline of forced vital capacity (FVC) when the patient was on supine position was recorded. In the absence of specific limb electrophysiological abnormalities, acute bilateral symmetric phrenic neuropathy was diagnosed. The patient was a borderline candidate for mechanical ventilation for 3 weeks. Conservative treatment with oxygen was administered and both respiratory and liver disorder resolved 4 weeks following admission. A causal relationship of phrenal neuropathy with adalimumab is herein discussed.
References
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285
Sandborn WJ, Rutgeerts P, Enns R et al (2007) Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146:829–838
Katsambas A (2008) Treating psoriasis as a chronic systemic inflammatory disease. Br J Dermatol 158:558–566
Papoutsaki M, Costanzo A, Chimenti MS, Chimenti S (2008) Adalimumab for the treatment of severe psoriasis and psoriatic arthritis. Expert Opin Biol Ther 8:363–370
Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87:210–219
Stübgen JP (2008) Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37:281–292
Chan CK, Loke J, Virgulto JA, Mohsenin V, Ferranti R, Lammertse T (1988) Bilateral diaphragmatic paralysis: clinical spectrum, prognosis, and diagnostic approach. Arch Phys Med Rehabil 69:976–979
Kumar N, Folger WN, Bolton CF (2004) Dyspnea as the predominant manifestation of bilateral phrenic neuropathy. Mayo Clin Proc 79:1563–1565
Gilchrist JM (2002) Overview of neuromuscular disorders affecting respiratory function. Semin Respir Crit Care Med 23:191–200
Valls-Solé J, Solans M (2002) Idiopathic bilateral diaphragmatic paralysis. Muscle Nerve 25:619–623
Nardone R, Bernhart H, Pozzera A, Taddei M, Tezzon F (2000) Respiratory weakness in neuralgic amyotrophy: report of two cases with phrenic nerve involvement. Neurol Sci 21:177–181
Lin PT, Andersson PB, Distad BJ et al (2005) Bilateral isolated phrenic neuropathy causing painless bilateral diaphragmatic paralysis. Neurology 65:1499–1501
Tsao BE, Ostrovskiy DA, Wilbourn AJ, Shields RW Jr (2006) Phrenic neuropathy due to neuralgic amyotrophy. Neurology 66:1582–1584
Lahrmann H, Grisold W, Authier FJ, Shields RW Jr (1999) Neuralgic amyotrophy with phrenic nerve involvement. Muscle Nerve 22:437–442
Thiéfin G, Morelet A, Heurgué A, Diebold MD, Eschard JP (2008) Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 75:737–739
García Aparicio AM, Rey JR, Alvarez JS (2007) Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 26:811–813
Disclosures
None
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexopoulou, A., Koskinas, J., Soultati, A. et al. Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin Rheumatol 28, 1337–1340 (2009). https://doi.org/10.1007/s10067-009-1241-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-009-1241-9